Lahore general.hospital, Lahore, Punjab Province, Pakistan - 01 May `25COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

Official title: COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

Status: Enrolling by invitation

Description:

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Phase: Early Phase 1.

What is being studied: drugs — Tacrolimus, Calcipotriol.

Who can take part: ages 15 Years to 70 Years, 60 participants planned.

Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 01 May 2025 and was due to finish 30 August 2025.

Source: ClinicalTrials.gov, NCT06880042 (https://clinicaltrials.gov/study/NCT06880042).

Start date: May 01, 2025

Completion date: August 30, 2025

Organizer: Dr ayesha wahid

Link: https://clinicaltrials.gov/study/NCT06880042

The registry does not list a contact for this study. Use the link above to reach the study record on ClinicalTrials.gov.

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO . By submitting you agree to our Privacy Policy.

FAQOther Questions